WO2001071346A3 - Binding compounds for cc chemokine receptor 5 and methods for identifying them - Google Patents

Binding compounds for cc chemokine receptor 5 and methods for identifying them Download PDF

Info

Publication number
WO2001071346A3
WO2001071346A3 PCT/US2001/009155 US0109155W WO0171346A3 WO 2001071346 A3 WO2001071346 A3 WO 2001071346A3 US 0109155 W US0109155 W US 0109155W WO 0171346 A3 WO0171346 A3 WO 0171346A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying
binding compounds
chemokine receptor
compounds
Prior art date
Application number
PCT/US2001/009155
Other languages
French (fr)
Other versions
WO2001071346A2 (en
Inventor
John J Nestor Jr
Carol J Wilson
Raymond H See
Hehir Christina A Tan
Original Assignee
Consensus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/813,653 external-priority patent/US20020064770A1/en
Priority claimed from US09/813,448 external-priority patent/US20020142346A1/en
Priority claimed from US09/813,651 external-priority patent/US20030018438A1/en
Application filed by Consensus Pharmaceuticals Inc filed Critical Consensus Pharmaceuticals Inc
Priority to AU2001247674A priority Critical patent/AU2001247674A1/en
Priority to EP01920642A priority patent/EP1268523A2/en
Priority to JP2001569482A priority patent/JP2003528319A/en
Priority to CA002404139A priority patent/CA2404139A1/en
Publication of WO2001071346A2 publication Critical patent/WO2001071346A2/en
Publication of WO2001071346A3 publication Critical patent/WO2001071346A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Abstract

Compositions of binding compounds for CC chemokine receptor 5 and methods for identifying binding compounds for CC chemokine 5 receptor are provided. Also provided are therapeutic agents comprising such compounds.
PCT/US2001/009155 2000-03-21 2001-03-21 Binding compounds for cc chemokine receptor 5 and methods for identifying them WO2001071346A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001247674A AU2001247674A1 (en) 2000-03-21 2001-03-21 Binding compounds and methods for identifying binding compounds
EP01920642A EP1268523A2 (en) 2000-03-21 2001-03-21 Binding compounds for cc chemokine receptor 5 and methods for identifying them
JP2001569482A JP2003528319A (en) 2000-03-21 2001-03-21 Binding compounds to CC chemokine receptor 5 and methods for identifying them
CA002404139A CA2404139A1 (en) 2000-03-21 2001-03-21 Binding compounds and methods for identifying binding compounds

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US19129900P 2000-03-21 2000-03-21
US19099600P 2000-03-21 2000-03-21
US19094600P 2000-03-21 2000-03-21
US60/190,946 2000-03-21
US60/190,996 2000-03-21
US60/191,299 2000-03-21
US09/813,651 2001-03-20
US09/813,448 2001-03-20
US09/813,653 2001-03-20
US09/813,653 US20020064770A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds
US09/813,448 US20020142346A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds
US09/813,651 US20030018438A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds

Publications (2)

Publication Number Publication Date
WO2001071346A2 WO2001071346A2 (en) 2001-09-27
WO2001071346A3 true WO2001071346A3 (en) 2002-09-12

Family

ID=27558818

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2001/040345 WO2001070765A1 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and methods for identifying them
PCT/US2001/009160 WO2001070768A2 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and method for identifying them
PCT/US2001/009155 WO2001071346A2 (en) 2000-03-21 2001-03-21 Binding compounds for cc chemokine receptor 5 and methods for identifying them

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2001/040345 WO2001070765A1 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and methods for identifying them
PCT/US2001/009160 WO2001070768A2 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and method for identifying them

Country Status (5)

Country Link
EP (3) EP1268523A2 (en)
JP (2) JP2003528319A (en)
AU (3) AU2001253870A1 (en)
CA (3) CA2403784A1 (en)
WO (3) WO2001070765A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056581A2 (en) * 2003-12-10 2005-06-23 Universite De Lausanne Peptide able to specifically bind a chemokine receptor and use thereof
CA2579678A1 (en) * 2004-10-04 2006-04-13 Alchemia Limited Selective inhibitors
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
DK2606129T3 (en) * 2010-08-19 2015-06-29 Probiodrug Ag Glutaminyl cyclase crystal structure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLANPAIN: "CCR5 binds multiple CC-Chemokines: MCP-3 acts as a natural antagonist", BLOOD, vol. 94, 1999, pages 1899 - 1905, XP002196556 *
DATABASE INTERNET August 2000 (2000-08-01), KIBBLE; PAGES 1-5: "American Chemical Society 220th National Meeting (Part VII); 20-24 August 2000, Washington DC, USA", XP002196692 *
SUNDBERG: "High-throughput and ultra-high-throughput screening: solutions- and cell-based approaches", CURRENT OPINIONS IN BIOTECHNOLOGY, vol. 11, February 2000 (2000-02-01), pages 47 - 53, XP002196557 *
TARASOVA ET AL: "Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 34911 - 34915, XP002168073, ISSN: 0021-9258 *
YANOFSKY ET AL: "High affinity type I interleukin 1 receptor antagonists disocvered by screening recombinant peptide libraries", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, July 1996 (1996-07-01), pages 7381 - 7386, XP000985913, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1268520A2 (en) 2003-01-02
AU2001247674A1 (en) 2001-10-03
AU2001253870A1 (en) 2001-10-03
WO2001070768A3 (en) 2002-03-14
CA2404139A1 (en) 2001-09-27
WO2001071346A2 (en) 2001-09-27
JP2004502134A (en) 2004-01-22
CA2403788A1 (en) 2001-09-27
WO2001070765A9 (en) 2003-02-06
EP1268523A2 (en) 2003-01-02
CA2403784A1 (en) 2001-09-27
JP2003528319A (en) 2003-09-24
EP1268521A1 (en) 2003-01-02
WO2001070765A1 (en) 2001-09-27
WO2001070768A2 (en) 2001-09-27
AU2001247675A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
DZ3191A1 (en) Indazole compounds and pharmaceutical compositions inhibiting protein kinases, and methods of using the same.
AU3725300A (en) Interleukin 17 receptor-like protein
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU1621799A (en) Fungicidal compositions and methods, and compounds and methods for the preparation thereof
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
CA2237221A1 (en) Protein kinase c inhibitor
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
GB9903216D0 (en) Preservative compounds,compositions and methods of making and using the same
AU4851397A (en) Compositions for the preparation of leather
AU2001245987A1 (en) Compositions and methods for gene therapy
AU5565099A (en) Pharmaceutical compositions and methods for use
ZA989997B (en) Compositions of lipid lowering agents.
AU9742098A (en) Autophobic hairspray compositions
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU5090899A (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
WO2002057313A3 (en) Receptor-binding compounds and methods for identifying them
WO2001071346A3 (en) Binding compounds for cc chemokine receptor 5 and methods for identifying them
AU8898198A (en) Methods of identifying biological agent compositions
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 569482

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2404139

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001247674

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001920642

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920642

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001920642

Country of ref document: EP